Introduction: Asthma markedly diminishes quality of life due to limited activity, absences from
work or school and hospitalizations. Patients with severe asthma which are not controlled …

Omalizumab, a humanized mAb that binds to the CH3 domain near the binding site for the
high-affinity type-I IgE Fc receptors of human IgE, can neutralize free IgE and inhibit the IgE …

Asthma often progresses into adulthood from early-life episodes of adverse environmental
exposures. However, how the injury to developing lungs contributes to the pathophysiology …

Seventeen case series investigating the effects of omalizumab on patients with atopic
dermatitis included patients whose pretreatment serum IgE was above 700 IU/ml, the upper …

Background The monoclonal anti-IgE antibody omalizumab is used as add-on therapy for
improved asthma control in patients with severe persistent allergic bronchial asthma. The …

Purpose A case of persistent hematologic abnormalities in a patient receiving long-term
omalizumab therapy for severe asthma is reported. Summary During the course of her …

В последние десятилетия документально подтверждена молекулярная и клиническая
гетерогенность бронхиальной астмы (БА), определены эндотипы и клинические …

Представлены данные об использовании анти-lgE терапии с помощью препарата
Ксолар (омализумаб) в лечении неконтролируемой бронхиальной астмы (БА) у детей …

Первым таргетным (целевым) препаратом, который применяется у пациентов с
неконтролируемой среднетяжелой и тяжелой бронхиальной астмой (БА), стал анти …

The first targeted drug that is used for patients with uncontrolled moderate and severe atopic
asthma (BA) was anti-IgE drug omalizumab (Xolar®). This drug is prescribed to patients with …